We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




High Throughput System Automates Human Papillomavirus HR Test

By LabMedica International staff writers
Posted on 26 Dec 2011
A high throughput system automates the DNA extraction and detection steps of the Human Papillomavirus high risk (HPV HR) test allowing users to walk away after loading the instrument and return the next morning to review the test results.

The Hologic (Bedford, MA, USA) HPV HR test utilizes the Invader technology to detect 14 high-risk types of HPV that are associated with cervical cancer and precancerous lesions.
The US Food and Drug Administration (FDA; Silver Spring, MD, USA have approved the Cervista high throughput automation system for cervical cancer screening.

Better diagnosis and therapies have helped to reduce significantly the number of new cancer cases, advanced-stage tumors, and ultimately deaths from cervical cancer in particular, which is predominantly caused by HPV. More...
Next to breast cancer, cervical cancer remains the second most frequent cancer affecting women worldwide.

"Our new Cervista represents a significant addition to our molecular diagnostics product portfolio," said Rob Cascella, president and CEO of Hologic. "The Cervista HTA automation system automates the HPV HR test, providing higher throughput, improved chain of custody, and accurate results. We are extremely pleased to get this product approved as it materially changes the competitive landscape for Hologic."

Related Links:

Hologic
US Food and Drug Administration





Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.